ZYBT
Zhengye Biotechnology Holdin
NASDAQ · Pharmaceuticals
$0.84
+0.09 (+12.05%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.11M | 10.68M | 11.04M |
| Net Income | 2.69M | 1.92M | 1.97M |
| EPS | — | — | — |
| Profit Margin | 22.3% | 18.0% | 17.9% |
| Rev Growth | -0.1% | -5.4% | +15.2% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 9.50M | 11.04M | 9.33M |
| Total Equity | 25.46M | 25.42M | 24.63M |
| D/E Ratio | 0.37 | 0.43 | 0.38 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 3.66M | 3.67M | 3.48M |
| Free Cash Flow | 1.61M | 1.47M | 1.80M |